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Summary
Adaptations in neurons of the midbrain periaqueduc-
tal gray (PAG) induced by chronic morphine treatment
mediate expression of many signs of opioid with-
drawal. The abnormally elevated action potential rate
of opioid-sensitive PAG neurons is a likely cellular
mechanism for withdrawal expression. We report here
that opioid withdrawal in vitro induced an opioid-sensi-
tive cation current that was mediated by the GABA
transporter-1 (GAT-1) and required activation of pro-
tein kinase A (PKA) for its expression. Inhibition of
GAT-1 or PKA also prevented withdrawal-induced
hyperexcitation of PAG neurons. Our findings indi-
cate that GAT-1 currents can directly increase the ac-
tion potential rates of neurons and that GAT-1 may be
a target for therapy to alleviate opioid-withdrawal
symptoms.
Introduction
Opioids are intensely addictive, and cessation of their
chronic use is associated with a withdrawal syndrome
consisting of severe early physical symptoms and late
features such as craving. Relapse into drug-taking be-
haviors often occurs as a result of this withdrawal syn-
drome (Mattick and Hall, 1996; Williams et al., 2001),
which is thought to result from neuronal adaptations
that develop to restore homeostasis during chronic opi-
oid exposure (Himmelsbach, 1943). On cessation of
opioid administration, persistent counteradaptations in
critical brain regions are unmasked and cause the with-
drawal syndrome. A rebound increase of adenylyl cy-
clase/protein kinase A (PKA) signaling is one counter-
adaptation that has been implicated in the expression
of opioid-withdrawal signs (Sharma et al., 1975; Nestler
and Tallman, 1988; Terwilliger et al., 1991).
The midbrain periaqueductal gray (PAG) is crucial for
expression of many somatic signs of opioid withdrawal.
Studies using microinjections of opioid antagonists and
agonists indicate that the PAG is involved in the expres-
sion of physical withdrawal signs such as teeth chatter-
ing, wet-dog shakes, and eye twitch, as well as escape
behaviors and place aversion (Bozarth and Wise, 1984;
Stinus et al., 1990; Maldonado et al., 1995; Punch et
al., 1997). While opioid agonists acutely inhibit adenylyl
cyclase activity in the brain (Collier and Roy, 1974) and
specifically in the PAG (Fedynyshyn and Lee, 1989), there*Correspondence: bagleye@med.usyd.edu.auis a compensatory increase in adenylyl cyclase signaling
during chronic treatment with morphine in vitro (Sharma
et al., 1975; Avidor-Reiss et al., 1997) and in vivo (Terwil-
liger et al., 1991) resulting in rebound hyperactivity of
this cascade during withdrawal. Microinjections of PKA
inhibitors into the PAG attenuate a spectrum of opioid-
withdrawal behaviors similar to those induced by mi-
croinjections of opioid antagonists (Maldonado et al.,
1995; Punch et al., 1997). One cellular mechanism by
which elevated adenylyl cyclase signaling could pro-
duce behavioral signs of withdrawal is the hyperexcita-
tion of opioid-sensitive PAG neurons (Chieng and
Christie, 1996). Increased adenylyl cyclase signaling
has also been proposed to result in the increased action
potential rates of neurons in other brain regions during
opioid withdrawal (Kogan et al., 1992; Nestler et al., 1999;
Ivanov and Aston-Jones, 2001).
We aimed to determine adaptations in PAG neurons
that result in hyperexcitation of action potential rate
during withdrawal and whether PKA is involved in this
process. Whole-cell, cell-attached, and perforated
patch recordings of PAG neurons from mice chronically
treated with morphine were used to demonstrate that
opioid withdrawal increases a GABA transporter-1
(GAT-1) cation current. The increased GAT-1 current is
dependent on PKA activity and is associated with the
withdrawal-induced elevated action potential rate of
PAG neurons. Thus, we have established that opioid
withdrawal stimulates a GAT-1 current that increases
the excitability of PAG neurons and is dependent on
PKA activation.
Results
Opioid Withdrawal Elevates the Action
Potential Rate
We first tested whether opioid withdrawal affected the
action potential rate of mouse PAG neurons as it does
in the rat (Chieng and Christie, 1996). Slices from vehi-
cle- and morphine-treated mice were incubated in mor-
phine (5 µM), and the opioid antagonist naloxone (1 µM)
was added to cause withdrawal. The AMPA/kainate re-
ceptor antagonist CNQX (10 µM) and the GABAA/GABAC
antagonist picrotoxin (100 µM) were present during
these experiments. In slices from vehicle-treated con-
trol mice, naloxone superfusion produced a small
increase in action potential rate as measured using cell-
attached recordings (Figures 1A and 1C; increase from
2.7 ± 1.5 Hz to 3.8 ± 1.1 Hz, only physiologically healthy
neurons were analyzed, see Experimental Procedures).
In morphine-treated mice, naloxone produced a signifi-
cantly larger increase in action potential rate (Figures
1B and 1C; increase from 2.6 ± 0.36 Hz to 6.7 ± 1.05).
Thus, as in rat, opioid withdrawal hyperexcited mouse
PAG neurons.
Naloxone did not increase the action potential rate of
all neurons. However, not all PAG neurons are opioid
sensitive (Chieng and Christie, 1994; Osborne et al.,
1996; Vaughan et al., 2003), and withdrawal-induced
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bFigure 1. Opioid Withdrawal Elevates the Action Potential Rate in
CPAG Neurons
C(A and B) Spontaneous action potential currents were measured
Dduring cell-attached recordings (drug superfusion shown by bars).
(A) Naloxone (1 µM) increased the action potential rate of a control c
neuron maintained in morphine (5 µM). (B) Naloxone (1 µM) sub-
stantially increased the action potential rate of a neuron from a M
morphine-treated mouse maintained in morphine (5 µM). t(C) Normalized rate histograms (data point every 30 s) were gener-
dated. Action potential rate for each neuron was normalized to the
sfirst seven points (n = 33 for control, n = 40 for chronic morphine).
The naloxone-induced increase in the action potential rate of neu- m
rons from morphine-treated mice (filled circle) was significantly t
greater than control (open circle, 8 min time point, p < 0.05.) a
m
v
hyperexcitation occurs in opioid-sensitive but not o
-insensitive PAG neurons (Chieng and Christie, 1996). n
Because postsynaptic opioid sensitivity could not be c
determined during the cell-attached recordings in the a
present study, the average increase in excitability (Fig- a
ure 1C) represents an underestimate of the withdrawal t
excitation of opioid-sensitive neurons. c
s
Chronic Morphine Treatment Induces an Additional r
Opioid-Sensitive Conductance 2
G protein-gated inward rectifier potassium (GIRK) chan- 0
nels underlie the inhibition by morphine of PAG action d
potential rates in neurons from untreated animals n
(Chieng and Christie, 1994; Vaughan et al., 2003). How- v
ever, in morphine-treated rats, in vitro, withdrawal by 6
naloxone was not explained by reversal of opioid acti- s
vation of GIRK channels, because the current did not
reverse polarity at EK (Chieng and Christie, 1996). This d
suggests that withdrawal from chronic opioid treatment a
modulates an additional opioid-sensitive current. To al- W
low activation and therefore study of the withdrawal- M
induced current, slices from morphine- and vehicle- f
treated mice were spontaneously withdrawn (mor-hine-free ACSF for >1 hr). In slices from vehicle-
reated mice, the opioid agonist methionine-enkephalin
MENK, 30 µM) produced an outward current in PAG
eurons (Figure 2A, 39 of 42 neurons voltage clamped
t −56 mV) that resulted from potassium channel acti-
ation because the reversal potential of the current was
lose to the potassium reversal potential (Figures 2C
nd 2E; −110 mV ± 3 mV, n = 39; Ek calculated with the
ernst equation was −103 mV; nonreversing currents
ere assigned a nominal reversal potential of −136 mV,
he most negative potential that could be achieved
ithout disrupting recordings). By contrast, the MENK-
nduced outward current during spontaneous with-
rawal (Figure 2B) did not reverse polarity close to Ek,
ndicating that opioids no longer solely activated a K
onductance (Figures 2D and 2E; n = 37). The MENK-
nduced currents from both morphine- and vehicle-
reated mice were unaffected by blockers of synaptic
ransmission (CNQX [5–10 µM], picrotoxin [100 µM], or
icuculline methiodide [30 µM] and tetrodotoxin [TTX]
0.3–1 µM]), so the results with and without blockers
ere combined (Figure 2E). These synaptic transmis-
ion blockers were present in all subsequent experi-
ents, and TTX was included in all experiments not
xamining action potentials. The MENK-induced cur-
ents in slices from morphine-treated mice resulted
rom µ-opioid receptor activation, as they were fully
locked by the µ-opioid receptor-selective antagonist
TAP (1 µM; MENK current was 1 ± 2 pA at −56 mV in
TAP, n = 4). The µ-opioid receptor-selective agonist
AMGO (1 µM) also induced a nonreversing outward
urrent (16 ± 3 pA at −56 mV, n = 3).
The lack of a measurable reversal potential for the
ENK current during morphine withdrawal is consis-
ent with MENK simultaneously increasing and/or
ecreasing the activity of two conductances. These re-
ults therefore suggest that, after chronic opioid treat-
ent, withdrawal activates an additional opioid-sensi-
ive current that can be inhibited by readdition of opioid
gonists. An additional, non-GIRK opioid-conductance
ight also be occasionally modulated in neurons from
ehicle-treated mice (nonreversing MENK current in 4
f 39 cells). However, it is modulated in the majority of
eurons during opioid withdrawal (nonreversing MENK
urrent in 24 of 37 cells, χ2 = 24.36, p < 0.05). Addition-
lly, there may be some modulation of a conductance
part from GIRK channels in all neurons from morphine-
reated animals during withdrawal, because the MENK
urrents that reversed polarity positive of −136 mV did
o at significantly more negative potentials than in neu-
ons from vehicle-treated mice (withdrawal, −118.1 ±
.4, n = 13, versus vehicle, −107.9 ± 2 mV, n = 35; p <
.02). In addition to modulation of another conductance
uring withdrawal, MENK induced any current in fewer
eurons from morphine-treated mice (vehicle, 39 of 42,
ersus spontaneously withdrawn, 37 of 51 cells; χ2 =
.34, p < 0.05) and the amplitude of the current was
maller (Figure 2E).
The properties of the additional conductance were
etermined in isolation by blocking the GIRK channels
ctivated by MENK using BaCl2 (1–3 mM; North and
illiams, 1985). When GIRK channels were blocked,
ENK (30 µM) did not produce any current in neurons
rom vehicle-treated mice (Figure 2F, n = 5) but still pro-
duced a current in neurons from morphine-treated
GAT-1 Transporter Currents and Opioid Withdrawal
435Figure 2. Opioid Receptors Simultaneously
Couple to a Potassium Conductance and a
Cation Conductance during Spontaneous
Withdrawal
(A and B) Example traces of currents from
neurons voltage clamped at −56 mV in spon-
taneously withdrawn slices (drug superfu-
sion shown by bars). MENK (30 µM) induced
an outward current that was reversed by nal-
oxone (1 µM) in (A) a vehicle-treated neuron
and (B) a neuron from a morphine-treated
mouse.
(C and D) Currents produced by voltage
steps from −56 mV to −136 mV in −10 mV
increments in (C) a vehicle-treated neuron
and (D) a neuron from a morphine-treated
mouse before (left) and during MENK (30 µM)
application (right).
(E) Subtracted current-voltage relationships
for MENK (current in MENK − current during
control conditions). Reversal potentials were
determined at the point where they cross the
abscissa. The MENK current reversed polar-
ity near Ek in neurons from vehicle-treated
mice (n = 39, open circle), but not in neurons
from morphine-treated mice (n = 37, filled
circle).
(F) Subtracted current-voltage relationship
for MENK (MENK − control) in the modified
ACSF (including the addition of Ba2+ to block
the opioid-activated K+ current). In Ba2+,
MENK failed to produce a current in neurons from vehicle-treated mice (n = 4, open circle), but produced a current that reversed polarity at
−40 mV in neurons from morphine-treated mice (n = 4, closed circle).mice. This current was outward at more negative mem-
brane potentials and reversed polarity at −40 ± 10 mV
(Figure 2F, n = 4). This is consistent with previous find-
ings in rat, where the naloxone-induced depolarization
produced by withdrawal persisted in Ba2+ (Chieng and
Christie, 1996). In these experiments, the ACSF was
also modified to reduce activation of voltage-activated
Ca2+ (CdCl2), Na+ (TTX), and K+ conductances (TEACl);
to reduce neurotransmitter release (0 CaCl2, 10 mM
MgCl2); and to shift the reversal potential of mixed-cat-
ion conductances to more negative values (lower NaCl,
details in Experimental Procedures).
A current that reverses polarity at −40 mV in modi-
fied, low-sodium ACSF could be due to MENK-induced
activation of a Cl− conductance or a decrease in the
activity of a mixed-cation conductance. The conduc-
tance was not a Cl− conductance, because the reversal
potential of the current was 24 mV more positive than
ECl as determined by application of the GABAA receptor
agonist muscimol (3 µM, −64 ± 4 mV in modified ACSF
without picrotoxin, n = 4). Therefore, the reversal poten-
tial of the additional conductance in the modified ACSF
used here is consistent with MENK decreasing the ac-
tivity of a cation conductance during withdrawal and
can be described by a linear “cation” conductance
equation with a reversal potential of −40 mV (in modi-
fied, low-sodium ACSF, see Experimental Procedures,
Equation 1). While the MENK-induced current in neu-
rons from vehicle-treated mice was well modeled by
the equation for a GIRK conductance (see Experimental
Procedures, Equation 2, R2 = 0.999), the nonreversing
MENK-induced current in neurons from morphine-
treated mice was poorly fit by the GIRK equation (R2 =
0.002). However, it was well modeled by a combinationof an increased GIRK and decreased cation conduc-
tance, with a reversal potential of −27 mV (calculated
Erev for standard, normal sodium ACSF, see Experimen-
tal Procedures, Equation 3, R2 = 0.992). Therefore, the
nonreversing current MENK induced in morphine-
treated mice can be explained by simultaneous activa-
tion of the GIRK conductance and inhibition of a cat-
ion conductance.
One candidate for the opioid-sensitive cation con-
ductance is the hyperpolarization activated cation con-
ductance, Ih, which is inhibited by opioids in nodose
ganglion (Ingram and Williams, 1994) and hippocampal
neurons (Svoboda and Lupica, 1998). A small-ampli-
tude, time-dependent Ih current was observed in PAG
neurons from both morphine- and vehicle-treated ani-
mals (note the current relaxation at the very negative
potentials in Figures 2C and 2D), but the MENK-
induced current still failed to reverse polarity if the mea-
surements were taken before Ih was activated (begin-
ning of voltage step, n = 37). Moreover, the reversal
potential of the MENK-induced current in morphine-
dependent mice was unaffected by the Ih blocker
ZD7288 (50 µM), i.e., when Ih was blocked, the current
still did not reverse at EK, and its amplitude at −136 mV
was unaffected by ZD72888 (1 ± 3 pA reduction, Figure
3B, n = 4).
Inhibition of GAT-1 Abolishes Opioid Modulation
of the Cation Conductance
and Withdrawal Hyperexcitation
Acutely opioids inhibit GABA release in the PAG, but
one consequence of opioid withdrawal is a rebound
increase in synaptic release of GABA (Ingram et al.,
1998; Hack et al., 2003). Therefore, we considered
Neuron
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Figure 3. GAT-1 Inhibition Abolished Opioid Modulation of the Ca- N
tion Conductance p
h(A) Subtracted current-voltage relationships for MENK (MENK −
ccontrol). In neurons from morphine-treated animals, MENK currents
nfailed to reverse polarity before addition of the GAT-1 inhibitor
nNO711 (filled circle), but reversed polarity close to EK during su-
(perfusion of NO711 (10 µM, n = 7, filled triangle).
s(B) Reversal potential of the MENK-induced currents before and
pafter addition of GAT-1 inhibitors. In spontaneously withdrawn neu-
trons, the Ih blocker ZD72888 (50 µM) or GABA receptor antagonists
A(100 µM picrotoxin, 1 µM CGP55845) did not alter the reversal po-
itential of the MENK current, but when GAT-1 was inhibited byhether the opioid-sensitive cation conductance could
e due to a GABA-related conductance. The nonrevers-
ng opioid current and increased action potential rate
n neurons from morphine-treated mice persisted in the
resence of high concentrations of the GABAA and
ABAC receptor blocker picrotoxin (100 µM) and the
ABAB receptor blocker CGP55845 (1 µM, Figure 3B;
GP55845 was present in all subsequent experiments).
dditionally, the current did not reverse polarity close
o the reversal potential of GABA receptor currents.
The cation conductance activated by opioid with-
rawal could result from GABA transport activity, be-
ause the GABA transporter that is expressed in PAG
eurons, GAT-1 (Barbaresi et al., 2001), is electrogenic,
.e., GABA transport into neurons results in a net +1
nward charge movement (Mager et al., 1993). Addition-
lly, under some conditions the GAT-1 transporter may
lso have uncoupled and/or leak conductances (Mager
t al., 1993; Cammack and Schwartz, 1996). The selec-
ive nontransportable inhibitors of GAT-1, NO711 and
KF 89976A (Suzdak et al., 1992; Borden et al., 1994),
oth potentiated the currents induced by superfusion
f GABA (10 mM, 64 ± 12 pA at −56 mV, n = 8), indicat-
ng that they effectively inhibited GAT-1 activity (NO711
10 µM], 189.6% ± 17% of control, n = 4 and SKF
9976A [100 µM], 135% ± 12%, n = 4). The GABA-
nduced current was blocked by picrotoxin (100 µM).
Inhibition of GAT-1 with NO711 (10 µM) produced a
mall outward current (5.9 ± 2.3 pA, n = 5) in neurons
rom morphine-treated mice but failed to produce any
urrent in neurons from vehicle-treated mice (−1.27 ±
.6 pA), suggesting that GAT-1 activity is increased dur-
ng opioid withdrawal. MENK (30 µM) currents in neu-
ons from morphine-treated mice that failed to reverse
olarity in the absence of NO711 subsequently re-
ersed polarity close to EK in the presence of NO711
10 µM for 10 min; Figures 3A and 3B). Similarly, SKF
9976A (10–100 µM for 10 min) shifted the reversal po-
ential for the MENK-induced current close to EK (Fig-
re 3B; note that the mean reversal potential for with-
rawn PAG neurons before application of SKF 89976A
s shown to be less than −136 mV because a reversing
urrent was observed in one of these neurons [Erev =
120 mV]). NO711 and SKF 89976A did not affect the
eversal potential in neurons from vehicle-treated mice
Figure 3B).
These results indicate that during opioid withdrawal
AT-1 activity is increased and that when GAT-1 is in-
ibited MENK reverts to activating a potassium con-
uctance in neurons from morphine-treated mice. TheO711 (10 µM) and SKF89976A (10–100 µM), the current reversed
olarity close to EK. Filled bars, spontaneously withdrawn neurons;
atched bars, neurons from vehicle-treated animals. Arrows indi-
ate that the average current did not reverse polarity at the most
egative potential that could be tested (−136 mV). The number of
eurons is shown below the bars.
C) Subtracted current-voltage relationship for the MENK current
ensitive to NO711 (MENK in morphine-treated − MENK in mor-
hine-treated plus NO711 10 µM, n = 7, filled circles) is similar to
he additional MENK-blocked current after morphine treatment (in
CSF modified to block the opioid-activated K+ current, as shown
n Figure 2F, dashed line).
GAT-1 Transporter Currents and Opioid Withdrawal
437MENK current that is sensitive to inhibition by NO711
(Figure 3C, normal Na+ ACSF) had an extrapolated re-
versal potential of −30 mV, which is similar to that of
the GAT-1 current activated by GABA in Bergmann glia
(Barakat and Bordey, 2002). The reversal potential of
the NO711-sensitive current is 10 mV more positive
than that of the conductance inhibited by MENK during
opioid withdrawal in the low-Na+ external solution (Fig-
ure 2F, Na [30 mM] replaced with TEA [30 mM]), which
is the predicted shift in reversal potential for GAT-1 cur-
rents (Lu and Hilgemann, 1999).
Increased GABA Release during Withdrawal Does
Not Cause the GAT-1-Mediated Cation Current
Since there is an enhancement of GABA (but not gluta-
mate) release under some conditions during withdrawal
(Ingram et al., 1998; Hack et al., 2003), it is possible that
the increased GAT-1 activity observed during with-
drawal resulted from more transporter substrate. To
test whether synaptically released GABA is necessary
for activation of the current, we attempted to abolish
all release. Recent work has shown that activation of
phosphatidylinositol 3-kinase (PI3K) is necessary for
the delivery of synaptic vesicles to the readily releas-
able pool (RRP) after their liberation from the reserve
pool (Cousin et al., 2003). Inhibition of PI3K with wort-
mannin led to enhanced rundown of glutamatergic syn-
aptic transmission during repetitive stimulation in hip-
pocampal neurons (Cousin et al., 2003). To reduce
quantal release, slices were preincubated (R2 hr imme-
diately after dissection) in ACSF containing wortmannin
(5 M) to inhibit replenishment of the RRP and sucrose
(50 mM, osmolarity increase from 310 to 360 mOsmoll) to
exhaust vesicles already present in the RRP. This pre-
treatment profoundly reduced the frequency (Figures
4Ai and 4Aii) but not the amplitude (vehicle: 44 ± 4 pA,
n = 7, after pretreatment, 40 ± 9 pA, n = 6; spontane-
ously withdrawn: 57 ± 4.3 pA, n = 10, after pretreat-
ment, 49 ± 8 pA, n = 7) of miniature inhibitory post-
synaptic currents (mIPSCs) in slices from both
morphine- and vehicle-treated mice for at least 1 hr
after the incubation. The ACSF contained CNQX (5 M),
TTX (1 M), and CGP55845 (1 M). MENK (30 µM) cur-
rents in neurons from morphine-treated mice failed to
reverse polarity at the most negative potentials tested
(interleaved controls), but after pretreatment to abolish
synaptic release, the MENK current reversed polarity
close to EK (Figure 4Aiii). The pretreatment did not affect
the reversal potential of MENK currents in neurons from
vehicle-treated mice (Figure 4Aiii). Therefore, profoundly
reducing release of GABA (and other neurotransmitters)
abolishes opioid modulation of the GAT-1 current, indi-
cating that a dramatic reduction in the substrate re-
duced the activity of the transporter.
Conversely, to test whether increasing neurotransmit-
ter release is able to stimulate the current in untreated
mice, we raised extracellular osmolarity. Adding 50 mM
sucrose increased the rate of mIPSCs by 100% (Figures
4Bi and 4Bii), which is similar to the increase produced
by opioid withdrawal (Ingram et al., 1998; Hack et al.
2003). However, it did not alter the reversal potential of
the MENK currents (Figure 4Biii). Increasing extracellu-
lar GABA concentration using exogenous GABA alsofailed to induce the GAT-1-mediated cation current, be-
cause the reversal potential of superfused GABA was
close to ECl both in the absence and, when any current
was detected, in the presence of TTX, CNQX, bicucul-
line, picrotoxin, CGP55845, gabazine (20 µM), and
strychnine (3 µM) (−69 ± 3 mV, n = 11). Therefore, while
some spontaneous neurotransmitter release is required
for opioids to modulate the GAT-1 current after chronic
morphine treatment, increasing GABA release in control
slices or addition of exogenous GABA is not sufficient
to cause opioid modulation of GAT-1 or activation of
the transporter current.
GAT-1 Protein Expression Is Unchanged
by Opioid Withdrawal
Because increasing neurotransmitter release is not suf-
ficient to activate the GAT-1 mediated current, it is pos-
sible that the current occurs during withdrawal because
there is more GAT-1 protein. To examine this possibility,
slices of PAG were taken from control (four mice, 600
µm slice each mouse) and withdrawn mice (five mice)
and processed for quantitative immunoblotting for GAT-1
and a loading control, α-actinin. A representative immu-
noblot for GAT-1 is shown in Figure 5A, and the bar chart
summarizes the quantitative analysis of the gray value
of bands from all mice: with GAT-1 expressed relative
to α-actinin. There was no difference in the absolute
level of GAT-1 between vehicle-treated and withdrawn
mice (gray value: 135 ± 15 versus 130 ± 11) or the level
relative to the loading control protein (Figure 5A).
Although the immunoblots show that the total level of
GAT-1 immunoreactivity in the PAG was not altered we
also used immunohistochemistry to determine whether
chronic opioid treatement altered GAT-1 levels in a sub-
division of the PAG. GAT-1 immunoreactivity was con-
centrated throughout the PAG (Figure 5B) and appeared
as a punctate, dense reaction product that surrounded
cell bodies and outlined dendrites (Figure 5B, inset) and
closely resembled the anatomical pattern of GAT-1 im-
munoreactivity in the cat PAG (Barbaresi et al., 2001).
Electrophysiological recordings were made from ventro-
lateral PAG neurons. As the terminals of ventrolateral PAG
neurons may extend beyond the ventrolateral PAG, we
also examined GAT-1 immunoreactivity in the neighbor-
ing brain structures. Immunoreactivity for GAT-1 was
significantly greater in the lateral PAG and dorsal raphe
than in the ventrolateral PAG, but there was no differ-
ence in any region of the PAG or dorsal raphe between
vehicle-treated and withdrawn mice (Figure 5C). There-
fore, as no difference could be detected in the total
protein level of GAT-1 in the PAG during spontaneous
withdrawal using either Western blots or immunohisto-
chemistry, the additional GAT-1 current is not due to
more total GAT-1 protein.
PKA Activity Is Required for Opioid Modulation
of the Cation Conductance
and Withdrawal Hyperexcitation
The withdrawal-induced GAT-1 cation current could re-
sult from the elevated adenylyl cyclase/PKA signaling
that develops in PAG during opioid withdrawal (Maldo-
nado et al., 1995; Punch et al., 1997; Williams et al.,
2001). If so, the selective, membrane-permeable PKA
Neuron
438Figure 4. Profound Reduction of Spontaneous mIPSCs in Opioid-Dependent Neurons Abolished Opioid Modulation of the Cation Conductance
but Increased GABA Release in Control Neurons Did Not Mimic Opioid Withdrawal
(Ai) Example traces of mIPSCs from a neuron in a spontaneously withdrawn slice. Pretreatment with sucrose and wortmannin to deplete the
RRP of synaptic vesicles and prevent entry of vesicles into the RRP profoundly reduced mIPSC frequency. (Aii) Quantification of the mIPSC
frequency with or without wortmannin and sucrose pretreatment. Pretreatment significantly reduced the frequency in neurons from vehicle-
and morphine-treated mice (*p < 0.001). Filled bars, spontaneously withdrawn neurons; open bars, neurons from vehicle-treated mice. The
number of neurons is shown above or below the bars. (Aiii) Reversal potential of the MENK-induced currents with or without wortmannin and
sucrose pretreatment. After pretreatment, the MENK current in neurons from morphine-treated mice reversed polarity close to EK. Arrows
indicate that the average current did not reverse polarity at the most negative potential that could be tested (−136 mV).
(Bi) Example traces of mIPSCs from a control neuron before and during sucrose. Raising osmolarity by adding sucrose increased the mIPSC
frequency. (Bii) Quantification of the mIPSC frequency before or during sucrose. Sucrose (50 mM) significantly increased the frequency of
mIPSCs in neurons from control mice (paired Student’s t test, *p < 0.03). (Biii) Reversal potential of the MENK-induced currents with or without
sucrose. High osmolarity did not alter the reversal potential of the MENK current.inhibitor RP-8-cpt-cAMPS or the nonselective protein P
Pkinase inhibitor staurosporine should block the MENK-
induced current. MENK (30 µM) currents in neurons G
sfrom morphine-treated mice that did not reverse polar-
ity prior to RP-8-cpt-cAMPS reversed polarity close to
EK in the presence of RP-8-cpt-cAMPS (100 µM for 10 A
Omin; Figures 6A and 6B). Similarly, in cells incubated in
staurosporine (1 µM for >1 hr), the current produced by I
dMENK (30 µM) reversed polarity closer to the predicted
EK (Figure 6B). RP-8-cpt-cAMPS did not alter the MENK- i
finduced current in neurons from vehicle-treated mice
(Figure 6B). These data suggest that during withdrawal, wKA activation stimulates the activity of GAT-1, and if
KA is inhibited during withdrawal, the stimulation of
AT-1 activity is prevented and MENK reverts to exclu-
ively modulating a GIRK conductance.
denylyl Cyclase Activation Mimics
pioid Withdrawal
f induction of the GAT-1 cation current during with-
rawal is produced as a result of increased PKA activ-
ty, then increasing adenylyl cyclase activity in neurons
rom untreated mice should mimic the effect of opioid
ithdrawal in a GAT-1-dependent manner. Increasing
GAT-1 Transporter Currents and Opioid Withdrawal
439Figure 5. Expression of GAT-1 Is Unchanged in PAG by Opioid With-
drawal
(A) Opioid withdrawal does not alter total GAT-1 immunoreactivity.
Example immunoblot showing GAT-1 immunoreactivity in lysates of
PAG from vehicle-treated and morphine-treated mice after induc-
tion of withdrawal in vivo with naloxone. The graph quantifies GAT-1
immunoreactivity in vehicle- or morphine-treated mice as a per-
centage of the immunoreactivity for the loading control protein
α-actinin. Filled bars, spontaneously withdrawn neurons; hatched
bars, neurons from vehicle-treated mice.
(B) GAT-1 immunoreactivity was differentially distributed in different
columns of the PAG. Broken lines mark boundaries of the lateral
(L), ventrolateral (VL) PAG, and dorsal raphe (DR) nucleus. Inset
shows punctate blue/black GAT-1 staining surrounding PAG cells.
Scale bars: main, 250 µm; inset, 15 µm.
(C) The graph quantifies the gray value of GAT-1 immunoreactivity.
GAT-1 immunoreactivity differed significantly (*p < 0.05) among dif-
ferent columns of the PAG, but was not different between vehicle-
treated (hatched bars) and morphine-treated mice (filled bars). The
number of animals is shown above the bars.adenylyl cyclase activity using forskolin (10 µM) in-
duced an inward current that was blocked by NO-711
(1 µM) in neurons from vehicle-treated mice (Figure 6C,
n = 4), but without PKA activation, NO-711 did not
block a current in vehicle-treated mice. Therefore, PKA
activation can stimulate a GAT-1 current, and this sug-
gests that opioids modulate a single additional conduc-
tance during withdrawal that relies on PKA and is due
to activity of GAT-1. The inward current had a reversalpotential of −39 mV ± 10 mV (in modified, low-sodium
ACSF; Figure 6D, n = 7), which is both consistent with
activation of a cation conductance and very close to
the reversal potential of the cation conductance inhib-
ited by MENK in low-sodium ACSF during opioid with-
drawal (Figure 2F). Dideoxyforskolin (10 µM), an analog
of forskolin that does not activate adenylyl cyclase, did
not induce an inward current (dideoxyforskolin, −0.5 ±
1.7 pA, n = 4, versus forskolin, −9.5 ± 4.2 pA, n = 4 at
−110 mV).
MENK (30 µM) currents in neurons from untreated
mice that reversed polarity close to EK prior to applica-
tion of forskolin no longer reversed polarity at the most
negative potential tested (−136 mV) in the presence of
forskolin (10 µM for 10 min, n = 6, Figure 6B). After acti-
vation of a cation conductance by forskolin, the MENK
current in neurons from untreated mice resembled the
MENK current in neurons from morphine-treated mice
(Figure 2E). In both cases, the extrapolated reversal
potential of the additional cation current was close to
−30 mV (normal sodium ACSF). Therefore, the GAT-1-
mediated, opioid-sensitive cation conductance can be
prevented by inhibition of PKA activity in morphine-
dependent PAG neurons and rapidly stimulated by acti-
vation of adenylyl cyclase in neurons from untreated
animals. These results suggest that chronic opioid treat-
ment increases the activity of the adenylyl cyclase cas-
cade and that removal of opioid inhibition (i.e., with-
drawal) relieves inhibition of adenylyl cyclase and
allows activation of the GAT-1 conductance. Readdition
of opioid agonists (MENK) inhibits the conductance via
inhibition of adenylyl cyclase activity.
PKA-Dependent Activation of the GAT-1 Cation
Conductance Mediates Hyperexcitation of PAG
Neurons during Withdrawal
Although the opioid-sensitive GAT-1 current in mor-
phine-treated mice was small (Figure 3C; 3 pA at −56
mV), because the input resistance of mouse PAG neu-
rons was high (1.83 ± 0.32 G, −60 to −70 mV, n = 92)
this current would still be expected to depolarize the
neurons by approximately 5.5 mV. This depolarization
could be sufficient to produce the increased action po-
tential rate observed during opioid withdrawal, so we
tested whether preventing activation of the cation con-
ductance by inhibiting GAT-1 or PKA reduced the nalox-
one-precipitated withdrawal stimulation of action po-
tential rate in morphine-treated mice.
When all GABA receptors were blocked, synaptic
transmission blockers were present, and slices main-
tained in morphine (5 µM), the addition of naloxone (1
µM) produced a significantly larger increase in action
potential rate in neurons from morphine-treated mice
than in neurons from vehicle-treated mice (Figure 7A).
By contrast, in NO711 (10 µM for 10 min), the naloxone-
induced increase in action potential rate of neurons
from morphine-treated mice was similar to the increase
in neurons from vehicle-treated mice (Figure 7A).
NO711 did not affect the smaller response to naloxone
in vehicle-treated neurons (Figure 7A). These results
suggest that inhibition of GAT-1 prevents opioid modu-
lation of the cation conductance activated during opi-
oid withdrawal and this prevents the increase in action
potential rate produced by opioid withdrawal.
Neuron
440Figure 6. Opioid Modulation of the GAT-1 Conductance Depends on Activation of PKA
(A) Current-voltage relationships for MENK (30 µM, MENK − control). In neurons from morphine-treated animals MENK currents failed to
reverse polarity before addition of the PKA inhibitor RP-CPT-cAMPs (filled circle) but reversed polarity close to EK during superfusion of RP-
CPT-cAMPs (100 µM, n = 4, filled triangle).
(B) Reversal potential of the MENK-induced currents before and during modulation of PKA activity. When PKA was inhibited by RP-CPT-
cAMPs (100 µM) or staurosporine (1 µM) in spontaneously withdrawn neurons the MENK current reversed polarity close to Ek. In neurons
from control mice, activation of PKA, using forskolin (10 µM), mimics opioid withdrawal, as the MENK current no longer reverses polarity.
Filled bars, spontaneously withdrawn neurons; hatched bars, neurons from vehicle-treated mice; open bar, neurons from control mice. Arrows
indicate that the average current did not reverse polarity at the most negative potential that could be tested (−136 mV). The number of
neurons is shown below the bars.
(C) Example trace of currents from a neuron whole-cell voltage clamped at −56 mV (drug superfusion shown by bars). In a neuron sensitive
to MENK (30 µM), forskolin (10 µM) induced an inward current in a neuron from an untreated mouse that is inhibited during superfusion of
the GAT-1 inhibitor NO711 (10 µM).
(D) Subtracted current-voltage relationship for MENK current sensitive to RP-CPT-cAMPs (MENK before RP-CPT-cAMPS − MENK in RP-CPT-
cAMPs, 100 µM, n = 5, filled circle) in neurons from morphine-treated mice and the forskolin-induced current in neurons from untreated mice
(forskolin − control, 10 µM, n = 7, open diamond).The hyperexcitation of PAG neurons during with- f
sdrawal was also blocked by PKA inhibitors. When
slices from dependent mice were maintained in mor- a
Pphine (5 µM) and superfused with RP-CPT-cAMPs (100
µM for 10 min), subsequent naloxone (1 µM) cosuperfu- t
Gsion no longer produced a greater increase in action
potential rate than in vehicle-treated mice (Figure 7B). r
RP-CPT-cAMPs did not affect the naloxone response r
in neurons from vehicle-treated mice (Figure 7B). There- i
fore, PKA activity during opioid withdrawal is necessary t
for both activation of the GAT-1 cation conductance o
and the increased action potential frequency. C
J
Discussion a
pDuring opioid withdrawal, opioid-sensitive PAG neu-
rons fire action potentials more frequently than neuronsrom control animals (Chieng and Christie, 1996). In this
tudy, we have shown that opioid withdrawal activates
n opioid-sensitive cation current that is dependent on
KA activity and is due to GAT-1 activity. When activa-
ion of this current is prevented by inhibition of PKA or
AT-1, the elevated action potential rate of PAG neu-
ons during withdrawal is also prevented. The present
esults provide direct experimental evidence support-
ng the suggestion that enhanced PKA signaling causes
he increase in neuronal action potential rate during
pioid withdrawal (Kogan et al., 1992; Chieng and
hristie, 1996; Nestler et al., 1999; Ivanov and Aston-
ones, 2001) and identify the underlying ionic mech-
nism.
The fact that opioid withdrawal increased the action
otential rate of PAG neurons through GAT-1 was unex-
pected. While there are many examples of indirect ac-
GAT-1 Transporter Currents and Opioid Withdrawal
441Figure 7. Inhibition of GAT-1 or PKA Prevents Hyperexcitation of
Action Potential Frequency during Opioid Withdrawal
(A) The increase in action potential rate induced by naloxone was
significantly greater in neurons from morphine-treated than vehicle-
treated mice (*p < 0.05). GAT-1 inhibition by NO711 (10 µM) abol-
ished the increased action potential rate during withdrawal in neu-
rons from morphine-treated mice but had no effect on the increase
in action potential rate induced by naloxone in neurons from vehi-
cle-treated mice. Filled bars, spontaneously withdrawn neurons;
hatched bars, neurons from vehicle-treated mice. The number of
neurons is shown above the bars.
(B) The naloxone-induced increase in action potential rate was sig-
nificantly greater in neurons from morphine-treated than vehicle-
treated mice (*p < 0.05). PKA inhibition by RP-CPT-cAMPS (100 µM)
abolished the increased action potential rate during withdrawal in
neurons from morphine-treated mice (*p < 0.05) but had no effect
on the increase in action potential rate induced by naloxone in neu-
rons from vehicle-treated mice.tions of GAT-1 inhibitors resulting from increased extra-
cellular GABA (e.g., Isaacson et al., 1993), a direct
effect of GAT-1 currents on action potential rate has not
been shown. In fact, only dopamine transporter cur-
rents have been shown to directly alter neuron action
potential rate (Ingram et al., 2002). An elevated action
potential rate or depolarization due to activation of
GAT-1 might be predicted by the inward current in-
duced by activating GABA transporters in horizontal
retinal cells (Malchow and Ripps, 1990; Cammack and
Schwartz, 1993) or GAT-1 in Bergmann glia (Barakat
and Bordey, 2002). An indirect effect of GAT-1 inhibition
is unlikely to account for the block of the cation con-
ductance and the increased action potential rate ob-
served in this study, as all GABA receptors were
blocked and the reversal potential of the current was
distinct from the reversal potential of GABA receptor
currents.The reversal potential and direction of ion flux of the
cation current were similar to those of the cloned GAT-1
transporter (Risso et al., 1996) and pharmacologically
defined GAT-1 conductances in Bergman glia (Barakat
and Bordey, 2002). The reversal potential of the cation
conductance could reflect reversal of the transporter or
the activity of a nonstoichiometric GAT-1 current. It is
possible that this reflects transport reversal because it
is likely that physiological levels of intracellular GABA
were maintained in the perforated patch recording con-
figuration, which are the conditions previously shown
to be required to observe transport reversal (Cammack
and Schwartz, 1993; Risso et al., 1996; Barakat and
Bordey, 2002). NO-711 and SKF-89976A are highly se-
lective for GAT-1 among the four cloned GABA trans-
porters (Suzdak et al., 1992; Borden et al., 1994), and at
the concentrations used in this study, other nonspecific
effects of NO711 and SKF-89976A are unknown; no ef-
fects were detected in neurons from vehicle-treated
mice. Additionally, NO711 lacks affinity for many other
transporters, ion channels, and receptors—specifically
the µ- and κ-opioid receptors (Suzdak et al., 1992).
Supporting the involvement of GAT-1, the presence of
some substrate was necessary for the transporter to
be active, as a dramatic reduction of vesicular GABA
release prevented opioid modulation of the current.
As in other brain regions, GAT-1 immunoreactivity
was detected in PAG neurons that were mainly (al-
though not exclusively) thought to be GABAergic inter-
neurons based on anatomical criteria (Barbaresi et al.,
2001). It is likely that the neurons in which we observed
the opioid-sensitive cation current and the increased
excitability were GABAergic neurons, as many PAG
neurons express immunoreactivity for both GABA and
the µ-opioid receptor (Kalyuzhny and Wessendorf,
1998). Further, neurons which express c-Fos immunore-
activity (a marker for raised neuronal activity) during
opioid withdrawal are likely to be GABAergic interneu-
rons, as they do not project to the rostral ventromedial
medulla (Bellchambers et al., 1998). Therefore, the ad-
ditional conductance modulated by opioids during
withdrawal from chronic opioids was qualitatively sim-
ilar to GAT-1, blocked by GAT-1 inhibitors, prevented
when GABA release was almost abolished, and likely
occurred in GABAergic neurons.
The opioid-sensitive cation conductance described
in this study relies on intact PKA signaling. It is unlikely
that PKA phosphorylation directly modifies GAT-1 activ-
ity, as the only consensus site for PKA phosphorylation
is extracellular (Guastella et al., 1990). The effect of ac-
tivation of PKA on the GAT-1 transporter has not been
comprehensively studied, but the subcellular location,
enzymatic activity, and absolute level of GAT-1 is regu-
lated in a complex inter-related manner by PKC activity,
GABA concentration, ionic conditions, tyrosine kinase
activity, and the release protein syntaxin 1A (Beckman
et al., 1998; Beckman and Quick, 1998; Whitworth and
Quick, 2001; Quick, 2002). It is possible that PKA indi-
rectly modifies the transporter activity through one of
these regulatory mechanisms. Indeed, PKA stimulation
indirectly increases GABA transporter activity in the
striatum, and morphine reduces this stimulated activity
(Schoffelmeer et al., 2000). Acute stimulation of ade-
nylyl cyclase in control PAG neurons was able to acti-
vate the cation conductance, suggesting that GAT-1
Neuron
442can be acutely regulated by adenylyl cyclase activity. i
Since there is a rebound PKA-dependent enhancement t
of GABA release during withdrawal (Ingram et al., 1998) w
and stimulating adenylyl cyclase also increases GABA n
release in untreated animals, we considered the possi-
bility that increased GAT-1 activity observed during E
withdrawal results from PKA stimulating GABA release,
Cthus providing more transporter substrate. However,
Mincreasing GABA release or adding exogenous GABA
i
in control animals did not produce a detectable GAT-1 C
current or produce opioid modulation of a non-GIRK w
current. Therefore, increased substrate concentration a
walone was not sufficient to allow activation of GAT-1. As
0the total protein level of GAT-1 is not altered after
Vchronic opioid treatment, this indicates that the
mincreased GAT current during withdrawal was not due
to an increase in the total number of GAT-1. Indeed, the
Trapid increase in GAT-1 current with PKA stimulation in
P
control animals is inconsistent with synthesis of new w
proteins, but it is possible that PKA activation increases i
the GAT-1 current by translocating the transporters to w
Athe cell surface. PKA activity could relocate transpor-
Nters to the cell surface because PKA phosphorylates
1and alters the interaction of proteins that bind to
t
syntaxin-1 (Evans et al., 2001; Boczan et al., 2004). 0
Syntaxin-1 directly interacts with GAT-1, and this in- m
teraction regulates the level of GAT-1 on the cell surface s
w(Deken et al., 2000).
oThe withdrawal signs mediated by the PAG are pre-
tvented by inhibition of PKA activity in the PAG (Maldo-
Cnado et al., 1995; Punch et al., 1997). Therefore, it is
likely that the GAT-1 depolarizing current that results in P
increased action potential rate together with increased (
GABA release probability (Ingram et al., 1998) are the E
amechanisms underlying the PKA-sensitive withdrawal
fbehaviors mediated by the PAG. It has been proposed
mthat GABAergic inhibition of PAG projection neurons to
c
the medulla during opioid withdrawal ultimately results t
in the expression of physical signs of withdrawal 2
(Chieng and Christie, 1996). The activation of the GAT-1 t
ocurrent and increased action potential rate shown here
would be expected to increase GABA release and
thereby inhibit PAG projection neurons. Therefore, E
Cthrough GAT-1 inhibition it might prove possible to se-
flectively inhibit the expression of opioid withdrawal by
preventing PAG neuronal hyperexcitability.
m
Neurotransmitter transporters may be a new family of e
proteins whose activity is altered as a result of chronic
opioid treatment. It is possible that the adaptations de-
Uscribed here as well as other modifications of neuro-
Etransmitter transporter activity may also occur in brain
regions where increased PKA signaling (Terwilliger et w
al., 1991) or neuronal hyperexcitability has been ob-
served (Baraban et al., 1995; Haghparast et al., 1998).
Several studies have shown that glutamate transporter
W
levels are altered by chronic opioid treatment (Ozawa p
et al., 2001; Mao et al., 2002), suggesting that neuro- f
transmitter transporters may prove to be useful targets
dfor management of opioid dependence. GAT-1 trans-
cport inhibitors are currently used to treat epilepsy and
are thought to reduce seizures by increasing the extra-
c
cellular GABA concentration. Our data indicates that
under certain conditions GAT-1 currents induce hyper-
excitability of central neurons, suggesting that GAT-1 Fnhibitors could produce their theurapeutic effect
hrough altering extracellular GABA concentrations as
ell as directly altering the excitability of GABAergic
eurons.
xperimental Procedures
hronic Treatment with Morphine
orphine dependence was induced by a series of subcutaneous
njections of sustained-release morphine suspension into male
57B16/J mice (300 mg/kg morphine base). Injections (0.1–0.2 ml)
ere made under light halothane anesthesia on days 1, 3, and 5,
nd mice were used for experiments on days 6 or 7. Morphine base
as suspended in 0.1 ml mannide mono-oleate (Arlacel A, Sigma),
.4 ml light liquid paraffin and 0.5 ml 0.9% w/v NaCl in water.
ehicle-treated mice were injected on the same schedule with
orphine-free suspension.
issue Preparation and Recordings
AG slices (220–250 µm) were cut from 4- to 6-week-old mice and
ere maintained at 34°C in a submerged chamber containing phys-
ological saline (ACSF) equilibrated with 95% O2 and 5% CO2 and
ere later transferred to a chamber superfused at 2 ml/min with
CSF (34°C) for recording. The standard ACSF contained 126 mM
aCl, 2.5 mM KCl, 1.4 mM NaH2PO4, 1.2 mM MgCl2, 2.4 mM CaCl2,
1 mM glucose, and 25 mM NaHCO3. The modified ACSF con-
ained 96 mM NaCl, 30 mM TEACl, 5 mM HEPES, 2.5 mM KCl,
mM NaH2PO4, 10 mM MgCl2, 0 mM CaCl2, 5 mM NaHCO3, 11
M glucose, 0.01 mM CdCl2, and 0.0003 mM tetrodotoxin. Brain
lices from both morphine-dependent and vehicle-treated mice
ere maintained in vitro in ACSF containing 5 µM morphine. Unless
therwise stated, slices were spontaneously withdrawn by incuba-
ion in morphine-free ACSF for at least 1 hr before an experiment.
GP55845 was a gift from Ciba Ltd (Basel, Switzerland).
PAG neurons were visualized using infra-red Nomarski optics.
erforated patch recordings were made using patch electrodes
4–5 m) filled with 120 mM K acetate, 40 mM HEPES, 10 mM
GTA, 5 mM MgCl2, with 0.25 mg/ml Pluronic F-127, 0.12 mg/ml
mphotericin B (pH 7.2, 290 mosmol/l). Liquid junction potentials
or K acetate internal solution of −8 mV with ACSF and −12 mV with
odified ACSF were corrected. Series resistance (<25 M) was
ompensated by 80% and continuously monitored. During perfora-
ed patch recordings, currents were recorded using a Axopatch
00A amplifier (Axon Instruments), digitized, filtered (at 2 kHz), and
hen acquired (sampling at 10 kHz) in pClamp (Axon Instruments)
r using Axograph Acquisition software (Axon Instruments).
quations
urrent-voltage curves were fit to the experimental data using the
ollowing equations.
The additional MENK-induced current in morphine-dependent
ouse neurons (Figure 2F) was fit with a curve described by the
quation
ICAT = gCAT(max)(V− ECAT(rev) ). (1)
sing this equation, it was found that gCAT(max) = −0.1 nS and that
CAT(rev) = −40 mV (low sodium).
The MENK-induced current in neurons from vehicle-treated mice
as fit with a GIRK conductance equation (Shen and North, 1992):
IK,IR = gk,IR(max) × (V− EK,IR) / [1 + exp((V− EK,IR) / factor)]. (2)
here the factor takes into account the inward rectification of the
otassium conductance. For control neurons (Figure 2E) it was
ound that gk,IR = 0.7 nS, Ek,IR = −103 mV, and factor = 169.
The MENK-induced current in neurons from morphine-
ependent mice (Figure 2E) was fit with a combination of the GIRK
onductance Equation 2 minus a cation conductance Equation 1:
ombination = gk,IR(max) × (V− EK,IR) / [1 +
exp((V− EK,IR) / factor)] − gCAT(max)(V− ECAT(rev) ). (3)
rom Equation 2, E was set at −103 mV, factor 169, and E =K,IR CAT(rev)
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443−27 mV (calculated ECAT(rev) for normal sodium conditions). It was
found that gk,IR(max) = 0.4 nS and gCAT(max) = 0.1 nS.
Cell-attached recordings were made using patch electrodes
(4–5 M) filled with K acetate solution, as above, but excluding
pluronic acid and amphotericin B. During cell-attached recordings,
capacitative action potentials were measured in voltage-clamp
without an applied command potential and were either recorded
on video tape (via Vetter PCM) and then later digitized offline in
Fetchex (sampling at 5 kHz) or acquired using Axograph. After the
cell-attached recording was completed, suction was applied to es-
tablish whole-cell current clamp recording to measure resting
membrane potential (RMP) and amplitude of action potentials.
Neurons were excluded from further analyses if the RMP was more
positive than −45 mV or if the action potential amplitude was less
than 50 mV. Data were then analyzed offline using Axograph. The
increase in action potential rate was calculated by subtracting the
3 min preceding naloxone from the last 2 min of naloxone.
To record GABAA mIPSCs, whole-cell voltage clamp recordings
were made using patch electrodes (2–5 M) containing 140 mM
CsCl, 10 mM EGTA, 5 mM HEPES, 2 mM CaCl2, and 2 mM MgATP
(pH 7.3, 270–290 mOsmol/l). Neurons were voltage clamped to −60
mV, and the series resistance (%12 M) was compensated by 80%
and continuously monitored during experiments. IPSCs were fil-
tered (1 kHz low-pass filter) and sampled at 5 kHz for online and
later offline analysis using Axograph 4.8. mIPSCs above a preset
threshold (4–5 standard deviations above baseline noise) were au-
tomatically detected by a sliding template algorithm, then were
manually checked offline.
SDS Page and Immunoblot
Ten minutes after withdrawal was induced by intraperitoneal injec-
tion of Naloxone (5 mg/kg), brain slices were cut. Finely chopped
PAG slices were homogenized and then lysed in ice-cold RIPA
buffer (1% Igepal, 0.5% Na Deoxycholate, 0.1% SDS in phosphate-
buffered saline [PBS]) with complete protease inhibitor (1:100,
Sigma) for 30 min. Homogenates were spun at 10,000 × g for 10
min at 4°C, and the supernatant protein concentration was deter-
mined (Bio-Rad Protein Assay). Sample supernatants (equivalent
protein amounts) were loaded on 10% gel (PAGEr Precast Gels,
Cambrex) and run at 125 V for 1 hr. Gels were transferred to
Immuno-blot PVDF membrane (Bio-Rad) at 100 V for 1 hr, and the
membranes were then blocked in 5% milk, 0.05% Tween 20 in
Tris-buffered saline (TBS) for 1 hr at room temp. Membranes were
cut and then incubated in either rabbit anti-GAT1 (1:500, Cat
AB1570W, Chemicon) or mouse anti-α-actinin (1:500, Upstate) for
1 hr at room temp. After washing in TBS, the membranes were incu-
bated in either HRP-conjugated goat anti-rabbit or goat anti-mouse
IgG (1:2000, Santa Cruz Biotechnology) for 1 hr at room temp. Mem-
branes were washed in TBS, and the activity of HRP conjugates
was determined using chemiluminescence (Biowest Extended Du-
ration Chemiluminescent Substrate) and film (Kodak Biomax light).
Immunolabeled bands were identified by their molecular weight
and quantified by densitometry (ImageJ 1.32, NIH).
Immunohistochemistry
Ten minutess after withdrawal was induced by intraperitoneal injec-
tion of Naloxone (5 mg/kg), mice were anaesthetised with Ketamine
hydrochloride and Xylazine hydrochloride and were transcardially
perfused with heparinized normal saline (10,000 IU/ml) followed by
cold 4% paraformaldehyde in 0.1 M phosphate buffer. Brains were
removed, postfixed in the same fixative for 4 hr at 4°C, and then cryo-
protected in 30% sucrose in PBS for 48 hr at 4°C. Coronal sections
(40 m) were cut through the PAG using a cryostat. Free-floating sec-
tions were washed in PBS and incubated in 50% ethanol and 3%
H2O2 in water for 20 min. After washing and blocking with 20% normal
horse serum (NHS) for 20 min, the sections were incubated in rabbit
anti-GAT-1 (1:250, Cat AB1570, Chemicon) with 5% NHS and 0.3%
Triton X-100 for 14 hr at room temp. After washing, sections were
incubated in biotinylated donkey anti-rabbit IgG (1:500, Amersham)
with 2% NHS for 3.5 hr at room temp, washed, and then incubated
in HRP conjugated ExtrAvidin (1:1000, Sigma) for 3.5 hr at room
temperature. Sections were processed for HRP histochemistry
using nickel enhanced DAB as the chromogen and glucose oxidaseas the catalyst, which results in a blue/black reaction product. All
sections were processed together using the same protocol, solu-
tions, and antibody mixes. Digitized images of the caudal PAG were
captured on a light microscope with a high-resolution CCD camera,
and ImageJ 1.32 was used to quantify immunoreactivity using den-
sitometry. The mean gray value (MGV) of each region was mea-
sured in four sections from each animal, and the average MGV from
the four sections was the result for the animal. The MGV of an
unlabeled region of the slice was subtracted to reduce back-
ground.
All experiments were approved by the Royal North Shore
Hospital/University of Technology Sydney Ethics committee. All
pooled data are expressed as mean ± SEM. Unless otherwise
stated, we tested for significance using the unpaired Student’s t
test.
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